Skip to main content

Horizon Discovery Inks Service Agreement with GSK

NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has signed a commercial service agreement with GlaxoSmithKline in the area of cancer metabolomics.

Under the agreement, Cambridge, UK-based Horizon will use its X-MAN cell lines to provide GSK with services including the characterization of biomarkers, disease signatures, and therapeutic targets.

Financial terms of the agreement were not disclosed.

Horizon said that its X-MAN isogenic cell lines provide genetically defined and patient-relevant in vitro models of human cancer to help companies discover and develop targeted or personalized cancer therapeutics.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.